Praxis RSV vaccine
Executive Summary
Phase I trials of a vaccine for respiratory syncytial virus currently in progress. Praxis is the first firm to have an RSV vaccine in clinicals. ICN's antiviral agent ribavirin is currently approved in the U.S. for treatment of the hospital-acquired infection. Bristol-Myers, which markets Praxis' pediatric vaccines and has an equity position in the Rochester-based firm, funded development of the RSV vaccine. Praxis now has five vaccines in human trials.